医学
三阴性乳腺癌
不利影响
临床试验
荟萃分析
乳腺癌
肿瘤科
内科学
癌症
作者
Gennaro Gadaleta-Caldarola,Laura Lanotte,Stefania Infusino,Arianna Gadaleta-Caldarola,Francesca Matilde Schipilliti,Claudia Citrigno,Cataldo Petrarota,Antonio Cusmai,Alessandro Rizzo
标识
DOI:10.1016/j.ctarc.2023.100775
摘要
TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd).Herein, we performed a meta-analysis aimed to evaluate any grade adverse events, grade 3-4 adverse events, dose reduction, and serious adverse events in TNBC patients treated with Dato-DXd in clinical trials.The pooled results suggests that Dato-DXd is associated with a favorable safety profile: while any grade treatment-related toxicities were common, grade 3-4 events were not particularly frequent and mainly represented by stomatitis (13.88%; 95% CI, 10.68 - 17.09).These findings may help to comprehensively define the safety profile of Dato-DXd and to assist in the design of future clinical trials in this setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI